drugset / Trial / NCT06836037

A Clinical Study of Efinopegdutide (MK-6024) in Healthy Chinese Volunteers (MK-6024-011)

NCT06836037

Phase 1 Completed 56 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindBasic science

Summary

The goal of this study is to learn about the safety and whether people tolerate a study medicine called efinopegdutide. The study will also measure what happens to efinopegdutide in a healthy person's body over time.

Timeline

Start
2022-09-05
Primary completion
2023-02-02
Completion
2023-02-02

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-64565111 Unknown Subcutaneous

Indications

No indication recorded.